Back to results
US 12,590,079 B2Granted
Compounds and uses thereof
AssigneeFoghorn Therapeutics Inc.
InventorsSabine K. Ruppel, Zhaoxia Yang, Jason T. Lowe
Life of this patent
Estimating the term…
Abstract
The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
Claims20
A compound having the structure of Formula I:
- A-L-B Formula I,
- wherein
- B is a degradation moiety,
- L is a linker, and
- A has the structure of Formula II:
- wherein
- the degradation moiety is a ubiquitin ligase binding moiety;
- R1 is, independently, H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, or optionally substituted C3-C10 carbocyclyl;
- Z1 is CR5 or N;
- R2 is, independently, H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C3-C10 carbocyclyl, optionally substituted C2-C9 heterocyclyl, optionally substituted C6-C10 aryl, optionally substituted C2-C9 heteroaryl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 heteroalkenyl, optionally substituted sulfone, or optionally substituted sulfonamide, or R2 and R3 together with the atoms to which each is attached, form an optionally substituted C2-C9 heterocyclyl;
- R3 and R4 are, independently, H, halogen, hydroxyl, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C3-C10 carbocyclyl, optionally substituted C2-C9 heterocyclyl, optionally substituted C6-C10 aryl, optionally substituted C2-C9 heteroaryl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 heteroalkenyl, thiol, optionally substituted sulfone, or optionally substituted amino, and/or R2 and R3 together with the atoms to which each is attached, form an optionally substituted C2-C9 heterocyclyl;
- R5 is H, halogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C3-C10 carbocyclyl, optionally substituted C2-C9 heterocyclyl, optionally substituted C6-C10 aryl, or optionally substituted C2-C9 heteroaryl;
- and
- G is
- G′ is optionally substituted C3-C10 carbocyclylene, C2-C9 heterocyclylene, optionally substituted C6-C10 arylene, or optionally substituted C2-C9 heteroarylene;
- and
- A1 is a bond between A and the linker,
- or a pharmaceutically acceptable salt thereof.
15 more elements
Dependencies are inferred from the claim text.